Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Prostate cancer podcast - The Xofigo   (radium-223 dichloride) series

Description

Xofigo, radium-223 dichloride, a treatment that has been indicated for the treatment of eligible men* with metastatic castration-resistant prostate cancer (mCRPC) for nearly 10 years. So, what is its role in today’s clinical practice? Listen to our 20-minute podcasts below to hear from multidisciplinary experts in prostate cancer.

 

Access each podcast episode below as well as a short reflective learning guide developed to empower your learning. Each learning guide includes:

 

  • Key learning points for each podcast.

  • Reflective learning questions to best improve the learnings from each episode and to aid application of knowledge.

  • A certificate of completion.

Why treat with Xofigo?

Why treat with Xofigo?

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible mCRPC patients in their clinics.
Episode 1
Dr Omi Parikh

Dr Omi Parikh

Consultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group.
Ellie Cradock

Ellie Cradock

Lead Molecular Radiotherapy Manager at the University Hospitals Bristol NHS Foundation Trust.

Optimising patient identification & referral

Optimising patient identification & referral

Hear from the perspective of both a leading oncologist and nuclear medicine consultant how they optimise the treatment and referral pathway for their patients.
 
Episode 2
Dr Julia Murray

Dr Julia Murray

Consultant clinical oncologist at The Royal Marsden NHS Foundation Trust and an honorary clinical senior lecturer at The Institute of Cancer Research, London, specialising in radiotherapy and systemic therapy for prostate cancer.
Dr Amy Eccles

Dr Amy Eccles

Consultant Radionuclide Radiologist and Clinical Lead for Nuclear Medicine at Imperial College Healthcare NHS Trust, London.

The Practicalities of treatment

The Practicalities of treatment

Gain valuable insights from leading healthcare professionals as they discuss what it means practically for the treating physicians, the multidisciplinary team and patients when going on treatment with radium-223 dichloride.
Episode 3
Dr Yeepei Song

Dr Yeepei Song

Consultant in Clinical Oncology at The Christie Hospital.
Dr Maryam Jessop

Dr Maryam Jessop

Chief Nuclear Medicine Technologist at Brighton and Sussex University Hospitals.

 

These promotional podcast series have been initiated and funded by Bayer UK and are for Healthcare professionals only.

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.

OPT-IN TO BAYER COMMUNICATIONS OPT-IN TO BAYER COMMUNICATIONS
FOOTNOTES

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email: pvuk@bayer.com.

 

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.